Memantina Jaba

Memantine Hydrochloride, the active ingredient in Memantina Jaba, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults, helping to reduce excitotoxic neuronal damage by non‑competitive antagonism of NMDA receptors, thereby decreasing calcium influx and neuronal injury associated with Alzheimer’s pathology.

GNH USA supplies Memantina Jaba as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides batch‑tested product for global distribution.

Memantina Jaba, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease.

Alzheimer’s disease (moderate to severe): improves cognition and functional abilities by reducing excitotoxic neuronal damage.

Memantina Jaba may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion

Serious or Rare Side Effects: - Hallucinations or psychosis - Severe hypertension - Allergic reactions such as skin rash or Stevens‑Johnson syndrome

Before initiating Memantina Jaba, clinicians should consider several precautionary measures to ensure safe use.

Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. Hepatic impairment: use with caution in patients with liver disease. Seizure history: monitor for increased seizure frequency. Concomitant NMDA antagonists: avoid combined use due to additive effects. Pregnancy and lactation: safety not established; weigh potential benefits against risks. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Memantina Jaba can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuropsychiatric adverse effects. - Dextromethorphan: additive NMDA blockade can lead to confusion and dizziness.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine): may blunt cognitive benefits; monitor response. - Antihypertensive agents: memantine may potentiate blood pressure lowering; observe blood pressure. - Diuretics: monitor electrolytes and renal function.